8 November marks the one-year anniversary of ‘Pfizer Monday’ – when stockmarkets surged following the news that Pfizer and BioNTech’s coronavirus vaccine was 90% effective in trials.
The increased likelihood that life would once again return to normal caused the MSCI All-Country World index to surpass its previous record high, while the FTSE 100 saw its biggest single-day jump since before the pandemic. It was after this that the ‘growth-versus-value' debate reared its head, with sectors that were particularly hard hit by Covid, as well as cyclical stocks, experiencing rapid rebounds. In an IW article published less than a week after the Pfizer announcement, Antipodes Partners' client portfolio manager Alison Savas said investors who "continue pouring into growth...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes